diff --git a/domains/health/lower-income-patients-show-higher-glp-1-discontinuation-rates-suggesting-affordability-not-just-clinical-factors-drive-persistence.md b/domains/health/lower-income-patients-show-higher-glp-1-discontinuation-rates-suggesting-affordability-not-just-clinical-factors-drive-persistence.md
index 9946497c..526b05f7 100644
--- a/domains/health/lower-income-patients-show-higher-glp-1-discontinuation-rates-suggesting-affordability-not-just-clinical-factors-drive-persistence.md
+++ b/domains/health/lower-income-patients-show-higher-glp-1-discontinuation-rates-suggesting-affordability-not-just-clinical-factors-drive-persistence.md
@@ -51,7 +51,7 @@ Aon's commercial claims data (employer-sponsored insurance) shows strong adheren
 
 
 ### Additional Evidence (extend)
-*Source: [[2026-03-20-stat-glp1-semaglutide-india-patent-expiry-generics]] | Added: 2026-03-20*
+*Source: 2026-03-20-stat-glp1-semaglutide-india-patent-expiry-generics | Added: 2026-03-20*
 
 OBBBA work requirements threaten to remove ~10M from Medicaid coverage precisely when international GLP-1 prices are dropping 50-90% but US prices remain patent-protected at $1,300/month through 2033. This creates structural access failure where coverage loss and price compression move in opposite directions for the population with highest metabolic disease burden.
 
diff --git a/inbox/queue/2026-03-29-circulation-cvqo-pcsk9-utilization-2015-2021.md b/inbox/queue/2026-03-29-circulation-cvqo-pcsk9-utilization-2015-2021.md
index 9e2cd24d..1288d3d3 100644
--- a/inbox/queue/2026-03-29-circulation-cvqo-pcsk9-utilization-2015-2021.md
+++ b/inbox/queue/2026-03-29-circulation-cvqo-pcsk9-utilization-2015-2021.md
@@ -45,7 +45,7 @@ Published in *Circulation: Cardiovascular Quality and Outcomes*, 2024. Large US
 **Context:** Search confirmed from multiple sources: PMC/CVQO trends study, JAHA adoption study, Amgen press release data. The pattern is consistent across data sources and time periods.
 
 ## Curator Notes
-PRIMARY CONNECTION: [[Session 13 claim candidate: access-mediated pharmacological ceiling]]; GLP-1 access archives (India generic vs. US patent); OBBBA coverage loss
+PRIMARY CONNECTION: Session 13 claim candidate: access-mediated pharmacological ceiling; GLP-1 access archives (India generic vs. US patent); OBBBA coverage loss
 WHY ARCHIVED: Quantitative anchor for access-mediated ceiling hypothesis — converts the "probably <5%" estimate from Session 13 into a documented 1–2.5% figure with specific primary source
 EXTRACTION HINT: Pair with SELECT trial CVD data and GLP-1 access barriers to build the complete "access-mediated pharmacological ceiling" claim. The pattern spans two drug generations (PCSK9 2015-2022, GLP-1 2024-present) — making it a structural pattern, not a one-time anomaly.